UBS Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target upped by UBS Group from $23.00 to $26.00 in a research note released on Wednesday,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other analysts have also recently issued reports on the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.14.

Teva Pharmaceutical Industries Trading Down 0.9%

TEVA stock opened at $19.28 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market cap of $22.11 billion, a price-to-earnings ratio of -120.51, a PEG ratio of 1.13 and a beta of 0.72. The business has a fifty day simple moving average of $17.69 and a 200-day simple moving average of $16.66. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. During the same quarter last year, the firm earned $0.61 earnings per share. The firm’s revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the company. Duquesne Family Office LLC raised its stake in Teva Pharmaceutical Industries by 65.4% during the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company’s stock valued at $228,702,000 after buying an additional 5,882,350 shares in the last quarter. Amundi raised its position in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company’s stock valued at $10,080,000 after acquiring an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd raised its position in shares of Teva Pharmaceutical Industries by 9.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock valued at $3,797,000 after acquiring an additional 19,447 shares in the last quarter. Jump Financial LLC lifted its stake in Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after purchasing an additional 838,423 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after purchasing an additional 134,705 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.